p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction

p53‐Dependent Mitochondrial Compensation in Heart Failure With Preserved Ejection Fraction

Background Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of patients with heart failure. Clinically, HFpEF prevalence shows age and gender biases. Although the majority of patients with HFpEF are elderly, there is an emergence of young patients with HFpEF. A better understa...

Bibliografske podrobnosti
Main Authors:	Xiaonan Chen, Hao Lin, Weiyao Xiong, Jianan Pan, Shuying Huang, Shan Xu, Shufang He, Ming Lei, Alex Chia Yu Chang, Huili Zhang
Format:	Article
Jezik:	English
Izdano:	Wiley 2022-06-01
Serija:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Teme:	aging HFpEF mitochondrial homeostasis p53 activation
Online dostop:	https://www.ahajournals.org/doi/10.1161/JAHA.121.024582

Podobne knjige/članki

The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
od: Becker Al-Khayatt, et al.
Izdano: (2024-05-01)

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
od: Satyam Sarma, et al.
Izdano: (2020-11-01)

iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation
od: Yongzheng Guo, et al.
Izdano: (2023-01-01)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
od: Bin Dong, et al.
Izdano: (2022-11-01)

The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
od: Clement Lau, et al.
Izdano: (2022-07-01)

Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
od: Ahmed Hamam, et al.
Izdano: (2022-12-01)

Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
od: Yohei Sotomi, et al.
Izdano: (2021-06-01)

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
od: Elisabeth A. Jalink, et al.
Izdano: (2024-01-01)

Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial
od: Kramer J. Wahlberg, et al.
Izdano: (2024-01-01)

Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data
od: Nazli Farajidavar, et al.
Izdano: (2022-12-01)

Proteomics and Precise Exercise Phenotypes in Heart Failure With Preserved Ejection Fraction: A Pilot Study
od: Ravi V. Shah, et al.
Izdano: (2023-11-01)

Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
od: José M. Inácio, et al.
Izdano: (2023-07-01)

Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
od: Alberto Palazzuoli, et al.
Izdano: (2023-01-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
od: Mariëlle Scheffer, et al.
Izdano: (2020-12-01)

Right Ventricular‐Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction
od: Zheng‐Wei Chen, et al.
Izdano: (2024-01-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
od: Arjun K. Pandey, et al.
Izdano: (2022-04-01)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
od: Zhen Hui Peh, et al.
Izdano: (2023-06-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
od: Mark Sweeney, et al.
Izdano: (2020-09-01)

The clinical relevance of quality of life in heart failure patients with preserved ejection fraction
od: Masahiro Seo, et al.
Izdano: (2023-04-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): A Case Report
od: Amanda Halimi, et al.
Izdano: (2021-09-01)

Myths and Facts About Heart Failure with Preserved Ejection Fraction: Risk Factors, Longevity, Potential Pharmacological and Exercise Interventions
od: Chung-Lieh Hung, et al.
Izdano: (2013-03-01)

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
od: Domenico D'Amario, et al.
Izdano: (2024-08-01)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
od: Xiao Wang, et al.
Izdano: (2024-11-01)

Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis
od: Shu Li, et al.
Izdano: (2023-08-01)

Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction
od: Dan Yin, et al.
Izdano: (2023-04-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
od: Christopher J. Charles, et al.
Izdano: (2020-10-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
od: Jenni Huusko, et al.
Izdano: (2020-06-01)

Diabetes and Excess Aldosterone Promote Heart Failure With Preserved Ejection Fraction
od: Bence Hegyi, et al.
Izdano: (2022-12-01)

Current Understanding of Molecular Pathophysiology of Heart Failure With Preserved Ejection Fraction
od: Heidi Budde, et al.
Izdano: (2022-07-01)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
od: Anita Pintér, et al.
Izdano: (2022-02-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
od: Stephanie J. Rowe, BBiomed, MD, et al.
Izdano: (2025-01-01)

Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
od: You Deng, et al.
Izdano: (2024-01-01)

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum
od: Karolina Andrzejczyk, et al.
Izdano: (2024-06-01)

Independent predictors of developing pulmonary hypertension in heart failure with reduced versus preserved ejection fraction
od: Alaa Roushdy, et al.
Izdano: (2017-07-01)

Age‐stratified profiles and outcomes of patients with heart failure with preserved ejection fraction
od: Shinsuke Yamanaka, et al.
Izdano: (2024-08-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
od: Kyle B. LaPenna, et al.
Izdano: (2021-03-01)

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
od: Natasha L. Patel‐Murray, et al.
Izdano: (2024-07-01)

Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
od: Min Chen, et al.
Izdano: (2024-12-01)

Effects of different exercise modalities on cardiac dysfunction in heart failure with preserved ejection fraction
od: David Bode, et al.
Izdano: (2021-06-01)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature [version 1; peer review: 2 approved]
od: Chanavuth Kanitsoraphan, et al.
Izdano: (2021-01-01)